SCHEMBL2137686

SCHEMBL2137686

Cn1ccnc1CC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.49
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.40
LPO P22079 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
ALOX12 P18054 1/20 0.39
HSD17B10 Q99714 1/20 0.39
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
ESR1 P03372 1/20 0.37
CNR2 P34972 1/20 0.36
ARG1 P05089 1/20 0.36
ARG2 P78540 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9715312 0.98 FDPS (0.47) FDPSKMT2AMEN1SMN1; SMN2LPO
SCHEMBL28245953 0.93 FDPS (0.44) FDPSKMT2AMEN1SMN1; SMN2LPO
SCHEMBL16767954 0.84 FDPS (0.49) FDPSKMT2AMEN1LPONPC1
SCHEMBL1075052 0.82 FDPS (0.51) FDPSKMT2AMEN1LPONPC1
SCHEMBL4877813 0.82 FDPS (0.47) FDPSKMT2AMEN1LPONPC1
SCHEMBL6497007 0.82 FPR2 (0.35) FDPSKMT2AMEN1SMN1; SMN2POLB
Hydrochloric Acid SCHEMBL8604193 0.81 FDPS (0.46) FDPSKMT2AMEN1SMN1; SMN2LPO
SCHEMBL693477 0.81 FNTA (0.47) FDPSKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL8607797 0.80 KMT2A (0.47) FDPSKMT2AMEN1LPOFNTA
Bromide SCHEMBL28813244 0.79 FNTA (0.46) FDPSKMT2AMEN1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4103946-B1 IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME IMMUNDIAGNOSTIK AG (DE) 2024-03-13 EP claimed
US-20230109016-A1 IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME IMMUNDIAGNOSTIK AG (DE) 2023-04-06 US claimed
EP-4103946-A1 IN-VITRO DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME Immundiagnostik AG (DE) 2022-12-21 EP claimed
EP-3805756-A1 SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT Metabolon, Inc. (US) 2021-04-14 EP claimed
US-20190310269-A1 SYSTEMS AND METHODS FOR MEASURING OBESITY USING METABOLOME ANALYSIS HUMAN LONGEVITY, INC. 2019-10-10 US claimed
CN-106537145-A Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment 麦特博隆股份有限公司 2017-03-22 CN claimed
EP-3129909-A1 SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT Metabolon, Inc. (US) 2017-02-15 EP claimed
CN-105885080-A Foamer composition and preparation method thereof 巨化集团技术中心 2016-08-24 CN claimed
WO-2015157407-A1 SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT METABOLON, INC. (US) 2015-10-15 WO claimed
WO-2013188333-A1 BIOMARKERS RELATED TO NEPHROTOXICITY AND METHODS USING THE SAME METABOLON, INC. (US) 2013-12-19 WO claimed
US-20100273207-A1 Methods for Diagnosis of Sepsis and Risk of Death LANGLEY RAYMOND 2010-10-28 US claimed
WO-2010124269-A1 METHODS FOR DIAGNOSIS OF SEPSIS AND RISK OF DEATH NATIONAL CENTER FOR GENOME RESOURCES (US) 2010-10-28 WO claimed
US-20260022384-A1 ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF OSPEDALE SAN RAFFAELE S.R.L. (IT) 2026-01-22 US disclosed
EP-4587116-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2025-07-23 EP disclosed
CN-116509847-B Application of 1,4-Methylimidazoleacetic acid in preparation of medicine for preventing and treating obesity 重庆医科大学 2025-05-23 CN disclosed
US-20240219399-A1 DIFFERENTIAL DIAGNOSIS OF HISTAMINE INTOLERANCE SYNDROME IMMUNDIAGNOSTIK AG (DE) 2024-07-04 US disclosed
EP-0240015-A2 Carbostyril derivatives, process for preparing them, pharmaceutical composition, and use OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-10-07 EP disclosed
US-4517254-A ALKALI METAL HYDROXIDE, AMINOALKYLPOLYACID COMPOUNT SCHERING AKTIENGESELLSCHAFT (DE) 1985-05-14 US disclosed
EP-0139090-A1 Process for the pre-treatment of polyimides SCHERING AKTIENGESELLSCHAFT (DE) 1985-05-02 EP disclosed
US-4248632-A ACTIVATION OF A POLYMER SURFACE WITH A PALLADIUM COMPLEX SALT SCHERING AKTIENGESELLSCHAFT (DE) 1981-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022384-A1 ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF ASNS, AARS1, NARS1 FDPS 284/4885KMT2A 2073/4885MEN1 4180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.